{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:42:57Z","timestamp":1769607777678,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,16]],"date-time":"2013-09-16T00:00:00Z","timestamp":1379289600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1756-8722-6-70","type":"journal-article","created":{"date-parts":[[2013,9,16]],"date-time":"2013-09-16T22:14:32Z","timestamp":1379369672000},"source":"Crossref","is-referenced-by-count":20,"title":["Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century"],"prefix":"10.1186","volume":"6","author":[{"name":"the GEKID Cancer Survival Working Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne","family":"Pulte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Eisemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Emrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Gondos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hentschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Holleczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Kraywinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,16]]},"reference":[{"issue":"9","key":"341_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/0145-2126(95)00032-J","volume":"19","author":"FL Meyskens Jr","year":"1995","unstructured":"Meyskens FL, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W, Hynes H: Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leuk Res. 1995, 19 (9): 605-612. 10.1016\/0145-2126(95)00032-J.","journal-title":"Leuk Res"},{"issue":"2","key":"341_CR2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V82.2.398.398","volume":"82","author":"R Hehlmann","year":"1993","unstructured":"Hehlmann R, Heimpel H, Hasford J: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993, 82 (2): 398-407.","journal-title":"Blood"},{"issue":"5","key":"341_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1634\/theoncologist.2010-0393","volume":"16","author":"D Pulte","year":"2011","unstructured":"Pulte D, Gondos A, Redaniel MT, Brenner H: Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist. 2011, 16 (5): 663-671. 10.1634\/theoncologist.2010-0393.","journal-title":"Oncologist"},{"issue":"12","key":"341_CR4","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","volume":"84","author":"R Hehlmann","year":"1994","unstructured":"Hehlmann R, Heimpel H, Hasford J: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994, 84 (12): 4064-4077.","journal-title":"Blood"},{"issue":"4","key":"341_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1056\/NEJM199707243370402","volume":"337","author":"F Guilhot","year":"1997","unstructured":"Guilhot F, Chastang C, Michallet M: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997, 337 (4): 223-229. 10.1056\/NEJM199707243370402.","journal-title":"N Engl J Med"},{"issue":"6","key":"341_CR6","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","volume":"84","author":"RA Clift","year":"1994","unstructured":"Clift RA, Bucknew CD, Thomas ED: Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994, 84 (6): 2036-2043.","journal-title":"Blood"},{"issue":"5","key":"341_CR7","first-page":"1810","volume":"91","author":"RP Gale","year":"1998","unstructured":"Gale RP, Hehlmann R, Zhang MJ: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood. 1998, 91 (5): 1810-1819.","journal-title":"Blood"},{"issue":"1","key":"341_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI9083","volume":"105","author":"BJ Druker","year":"2000","unstructured":"Druker BJ, Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhitior for chronic myelogenous leukemia. J Clin Invest. 2000, 105 (1): 3-7. 10.1172\/JCI9083.","journal-title":"J Clin Invest"},{"key":"341_CR9","first-page":"3","volume":"406","author":"European Medicines Agency (EMEA)","year":"2009","unstructured":"European Medicines Agency (EMEA): European public assessment report (EPAR) Glivec: EPAR summary for the public. EMEA\/H\/C. 2009, 406: 3-","journal-title":"EMEA\/H\/C"},{"key":"341_CR10","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002, 8: 935-942.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"341_CR11","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006, 355 (23): 2408-2417. 10.1056\/NEJMoa062867.","journal-title":"N Engl J Med"},{"issue":"6","key":"341_CR12","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009, 23 (6): 1054-1061. 10.1038\/leu.2009.38.","journal-title":"Leukemia"},{"issue":"5","key":"341_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012, 119 (5): 1123-1129. 10.1182\/blood-2011-08-376087.","journal-title":"Blood"},{"issue":"9","key":"341_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G: Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011, 12 (9): 841-851. 10.1016\/S1470-2045(11)70201-7.","journal-title":"Lancet Oncol"},{"issue":"10","key":"341_CR15","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3324\/haematol.13045","volume":"93","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D: Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica. 2008, 93 (10): 1544-1549. 10.3324\/haematol.13045.","journal-title":"Haematologica"},{"issue":"12","key":"341_CR16","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.leukres.2009.01.042","volume":"33","author":"H Brenner","year":"2009","unstructured":"Brenner H, Gondos A, Pulte D: Long-term survival in chronic myelocytic leukemia after a first primary malignancy. Leuk Res. 2009, 33 (12): 1604-1608. 10.1016\/j.leukres.2009.01.042.","journal-title":"Leuk Res"},{"issue":"8","key":"341_CR17","first-page":"1","volume":"123","author":"CL Wiggins","year":"2010","unstructured":"Wiggins CL, Harlan LC, Nelson HE: Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. M J Med. 2010, 123 (8): 1-9. 764.e","journal-title":"M J Med"},{"issue":"12","key":"341_CR18","first-page":"1733","volume":"119","author":"J Lamvik","year":"1999","unstructured":"Lamvik J, Brinch L, Dahl IM: Chronic myeloid leukemia in health regions 1,3,4, and 5 during the period 1990\u201396. Tidsskr Nor Laegeforen. 1999, 119 (12): 1733-1736.","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"16","key":"341_CR19","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1182\/blood-2011-01-330332","volume":"118","author":"S Corm","year":"2011","unstructured":"Corm S, Roche L, Micol JB: Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990\u20132007: a population study. Blood. 2011, 118 (16): 4331-4337. 10.1182\/blood-2011-01-330332.","journal-title":"Blood"},{"issue":"18","key":"341_CR20","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Ohm L, Eloranta S: Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011, 29 (18): 2514-2520. 10.1200\/JCO.2011.34.7146.","journal-title":"J Clin Oncol"},{"issue":"2","key":"341_CR21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/annonc\/mdr131","volume":"23","author":"E Hiripi","year":"2012","unstructured":"Hiripi E, Gondos A, Emrich K: Survival from common and rare cancers in Germany in the early 21st century. Ann Oncol. 2012, 23 (2): 472-479. 10.1093\/annonc\/mdr131.","journal-title":"Ann Oncol"},{"key":"341_CR22","volume-title":"Program (www.seer.cancer.gov) Research Data (1973\u20132008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released","author":"Surveillance, Epidemiology, and End Results (SEER)","year":"2011","unstructured":"Surveillance, Epidemiology, and End Results (SEER): Program (www.seer.cancer.gov) Research Data (1973\u20132008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released. 2011, April , based on the November 2010 submission"},{"key":"341_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/A:1014380323037","volume":"13","author":"A Mariotto","year":"2002","unstructured":"Mariotto A, Capocaccia R, Verdecchia A: Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes Control. 2002, 13: 101-111. 10.1023\/A:1014380323037.","journal-title":"Cancer Causes Control"},{"key":"341_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ejca.2003.10.013","volume":"40","author":"H Brenner","year":"2004","unstructured":"Brenner H, Gefeller O, Hakulinen T: Period analysis for up-to-date cancer survival data: theory, empirical evaluation, computational realization and applications. Eur J Cancer. 2004, 40: 326-335. 10.1016\/j.ejca.2003.10.013.","journal-title":"Eur J Cancer"},{"issue":"9","key":"341_CR25","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#","volume":"78","author":"H Brenner","year":"1996","unstructured":"Brenner H, Gefeller O: An alternative approach to monitoring cancer patient survival. Cancer. 1996, 78 (9): 2004-2010. 10.1002\/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#.","journal-title":"Cancer"},{"issue":"2","key":"341_CR26","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/ije\/31.2.456","volume":"31","author":"H Brenner","year":"2002","unstructured":"Brenner H, Soederman B, Hakulinen T: Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol. 2002, 31 (2): 456-462. 10.1093\/ije\/31.2.456.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"341_CR27","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.20.3.826","volume":"20","author":"H Brenner","year":"2002","unstructured":"Brenner H, Hakulinen T: Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol. 2002, 20 (3): 826-832. 10.1200\/JCO.20.3.826.","journal-title":"J Clin Oncol"},{"issue":"6","key":"341_CR28","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V66.6.1352.1352","volume":"66","author":"JE Sokel","year":"1985","unstructured":"Sokel JE, Baccarni M, Tura S: Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood. 1985, 66 (6): 1352-1357.","journal-title":"Blood"},{"issue":"7","key":"341_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/aje\/kwj243","volume":"164","author":"H Brenner","year":"2006","unstructured":"Brenner H, Hakulinen T: Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006, 164 (7): 689-696. 10.1093\/aje\/kwj243.","journal-title":"Am J Epidemiol"},{"key":"341_CR30","volume-title":"HH. Instructions to IBM 650 programmers in processing survival computations","author":"F Ederer","year":"1959","unstructured":"Ederer F: HH. Instructions to IBM 650 programmers in processing survival computations. 1959, Bethesda, MD: National Cancer Institute"},{"key":"341_CR31","first-page":"1","volume-title":"Natl Vit Stat Rep","author":"E Arias","year":"2002","unstructured":"Arias E: United States life tables, 2000. Natl Vit Stat Rep. 2002, 1-39."},{"key":"341_CR32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S0959-8049(02)00003-5","volume":"38","author":"H Brenner","year":"2002","unstructured":"Brenner H, Gefeller O, Hakulinen T: A computer program for period analysis of cancer patients survival. Eur J Cancer. 2002, 38: 690-695. 10.1016\/S0959-8049(02)00003-5.","journal-title":"Eur J Cancer"},{"issue":"6","key":"341_CR33","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/cncr.11629","volume":"98","author":"J Cortes","year":"2003","unstructured":"Cortes J, Talpaz M, O\u2019Brien S: Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003, 98 (6): 1105-1113. 10.1002\/cncr.11629.","journal-title":"Cancer"},{"issue":"21","key":"341_CR34","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F: Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011, 117 (21): 5591-5599. 10.1182\/blood-2010-12-324228.","journal-title":"Blood"},{"issue":"Suppl 3","key":"341_CR35","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdm095","volume":"18","author":"B Joensson","year":"2007","unstructured":"Joensson B, Wilking N: A global comparison regarding patient access to cancer drugs. Ann Oncol. 2007, 18 (Suppl 3): iii1-iii77.","journal-title":"Ann Oncol"},{"issue":"7","key":"341_CR36","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/cncr.22523","volume":"109","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Cortes J, Guilhot F, Hochhaus A, Baccarni M, Lokey L: Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer. 2007, 109 (7): 1365-1375. 10.1002\/cncr.22523.","journal-title":"Cancer"},{"key":"341_CR37","first-page":"1","volume":"132","author":"F Berrino","year":"1995","unstructured":"Berrino F, Esteve J, Coleman MP: Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ. 1995, 132: 1-14.","journal-title":"IARC Sci Publ"},{"issue":"5","key":"341_CR38","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ejca.2007.01.007","volume":"43","author":"D Robinson","year":"2007","unstructured":"Robinson D, Sankila R, Hakulinen T, Moller H: Interpreting international comparisons of cancer survival: the effects of incomplete registration and the presence of death certificate only cases on survival estimates. Eur J Cancer. 2007, 43 (5): 909-913. 10.1016\/j.ejca.2007.01.007.","journal-title":"Eur J Cancer"},{"issue":"12","key":"341_CR39","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/1055-9965.EPI-11-0697","volume":"20","author":"H Brenner","year":"2011","unstructured":"Brenner H, Holleczek B: Deriving valid population-based cancer survival estimates in the presence of nonnegligible proportions of cancers notified by death certificate only. Cancer Epidemiol Biomarkers Prev. 2011, 20 (12): 2480-2486. 10.1158\/1055-9965.EPI-11-0697.","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-6-70.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-6-70\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-6-70.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T03:56:51Z","timestamp":1596513411000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-6-70"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["341"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-6-70","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,16]]},"article-number":"70"}}